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Abstract
Background: Clinical disease activity index (CDAI) and simplified disease activity index (SDAI) are useful tools for
the evaluation of disease activity in patients with rheumatoid arthritis (RA), but have not been comparatively
validated in Moroccan population. Therefore, this study was designed to assess validity and reliability of CDAI and
SDAI in comparison to disease activity score-28 joints (DAS-28) in Moroccan patients with RA.
Methods: Patients with RA were included in a cross-sectional study. Patient characteristics and RA were collected. The
disease activity was assessed by DAS-28, CDAI and SDAI. Patients were splitted into groups of remission, low, moderate
and high activity on the basis of predefined cut-offs for DAS-28, CDAI, and SDAI. A Spearman correlation between
composite indexes and inter-group comparison of the indexes were performed. Using DAS-28 as a gold standard, the
Receiver operator characteristic (ROC) curve was used to assess the performance of a screening test at different levels.
Results: The study was conducted with 103 patients of female predominance (87.4 %). Mean age was 49.7 ± 11.4 years.
Median disease duration was in the order of 8 years [3-14]. There was an excellent correlation between DAS-28 and
CDAI (r = 0.95, p <0.001), CDAI and SDAI (r = 0.90, p <0.001), and DAS-28 and SDAI (r = 0.92, p <0.001). There was a
good inter-rater alignment between the DAS-28 and CDAI (Weighted kappa =0.743) and there was a moderate inter-
rater alignment between the DAS-28 and SDAI (Weighted kappa =0.60), and also between the SDAI and CDAI
(Weighted kappa = 0.589). There was no statistically significant difference between AUROC of CDAI and SDAI as both
were performed equally well.
Discussion: This study is the first Moroccan case study to compare the performance of both CDAI and SDAI in
evaluation of disease activity in patients with RA. Our study showed that there was a direct and excellent correlation
between DAS-28 and CDAI, and SDAI and DAS-28.
Conclusion: Our study shows a strong positive correlation between DAS-28, CDAI and SDAI. The cut-off values for
CDAI and SDAI used in western literature can be used with minor modifications in Moroccan scenario.
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease whose main characteristic is persistent joint inflam-
mation that results in joint damage and loss of functions.
These adverse consequences can be prevented, at least
partially, by early appropriate therapy, particularly a “tight
control” strategy [1]. Such strategy requires evaluating dis-
ease activity and reaction to treatment using objective and
standardized tools [2].
The currently available disease composite activity in-
dexes that provide a single number on a continuous scale
are the Disease Activity Score (DAS), the DAS using 28
joint counts (DAS- 28) [3], the Simplified Disease Activity
Index (SDAI) [3], and the Clinical Disease Activity Index
(CDAI) [3].
Until recently DAS-28 was the only gold standard to
measure the disease activity in patients with RA [4]. It
is recommended by the European League Against
Rheumatism (EULAR) [5]. DAS28 is calculated from the
number of tender and swollen joints (28-joint count),
patient self-assessment of disease activity (visual analog
scale), and ESR by the following formula: DAS28 = (0.56 *
tender joint count 1/2) + (0.28 * swollen joint count
1/2) + (0.7 * ln [ESR]) + (0.014*VAS) [6]. This means that
this formula requires very complicated calculation and
therefore a calculator is needed. So it is often difficult to
do it practically on a daily basis for patients consultation.
Clinical Disease Activity Index (CDAI) is a compos-
ite index (without acute-phase reactant) for assessing
disease activity. CDAI is based on the simple summa-
tion of the count of swollen/tender joint count of 28
joints along with patient and physician global assess-
ment on VAS (0–10 cm) Scale for estimating disease
activity [3]. The greatest advantage of CDAI is the omis-
sion of laboratory test. Therefore, it can essentially be used
everywhere and at anytime for disease activity assessment
on RA patients [7].
The simplified disease activity index (SDAI) is a quick
and convenient method for measuring rheumatoid arth-
ritis in a clinical environment. It is scored by simply
adding the numerical values corresponding to the follow-
ing set of predetermined elements: the 28 joint assessment
used to measure tender and swollen joint count; patient
and physician global assessment of disease activity mea-
sured using a visual analogue scale, and finally, levels of
the measured C-reactive protein (mgudl, normal <1
mgudl) [8].
The SDAI and CDAI were validated in the original
studies that were developed in using additional cohorts
of patients [9]. Therefore, the aim of the present study
was to assess disease activity in Moroccan patients with
RA using CDAI and SDAI and to evaluate reliability and
validity of CDAI and SDAI in comparison to DAS-28 in
Moroccan patients with rheumatoid arthritis.
Methods
A total of 103 RA cases were included in a cross-sectional
study in the Department of Rheumatology, at El Ayachi
hospital in Morocco, The period of data collection was
from October 2012 to March 2013. Patients were diag-
nosed to have RA by the rheumatologist according to
American College of Rheumatology (ACR 1987) classifica-
tion Criteria for RA [10]. Patients with diseases other than
rheumatoid arthritis were excluded from the study. Our
study is non-interventional and verbal consent was ob-
tained from all the patients. The study was approved by
ethics committee of our university hospital (El Ayachi
University-Hospital Sale, Morocco).
Disease history, clinical examination, and routine la-
boratory investigations including radiographical examin-
ation were all detailed for the subjects included in the
Table 1 Demographic and clinical characteristics of RA patients
(n = 103)
Characteristics N = 103
Age (Years mean ± SD) 49,7 ± 11,4
Sex (female/male) 90/13
Median duration of illness (per years) 8 (3–14)a
VAS (mean ± SD) (mm) 40 ± 29
HAQ 0,5 (0–1,37)a
DAS 28 ESR 4,27 ± 1,75
CDAI 13 (5,25)a
SDAI 24 (11,40)a
VAS Visual analogue scale of pain, HAQ Health assessment questionnaire,
DAS28 Disease activity for 28 joint indices score, ESR Erythrocyte
sedimentation rate, CDAI Clinical disease activity index, SDAI Simplified disease
activity index
amedian and quartiles (the 50th percentile)
Table 2 Distribution of patients with various levels of disease
activity and criteria used in our study
Index Disease of activity Definition Number of patients
DAS-28 ESR Remission <2.6 20
Low activity <3.2 20
Moderate activity <5.1 42
High activity ≥5.1 21
CDAI Remission <2.8 16
Low activity <10 25
Moderate activity <22 31
High activity ≥22 31
SDAI Remission <3.3 5
Low activity <11 19
Moderate activity <26 24
High activity ≥26 49
DAS28 Disease activity for 28 joint indices score, ESR Erythrocyte
sedimentation rate, CDAI Clinical disease activity index, SDAI Simplified disease
activity index
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study. All patients were asked about their age, duration of
the disease, visual analogue scale of pain (0–100 mm), the
morning stiffness in minutes, the number of swollen joints
(0–28) and tender joints (0–28), medication taken and
Erythrocyte sedimentation rate (ESR). The disease activity
was assessed by DAS-28 ESR, CDAI and SDAI.
Patients were splitted into groups of remission, low,
moderate and high activity on the basis of predefined cut-
offs for DAS-28, CDAI, and SDAI [9].
Statistical analysis: Statistical analysis was done using
statistical package for social sciences version 13 (SPSS
13.0) and MedCalc statistical software.
Spearman correlation coefficient (r) was used to assess
the correlation between continuous variables of indexes
(DAS-28, CDAI and SDAI). Weighted Kappa statistics
(Weighted K) were used to assess the alignment between
each score. We used Altman 1991 guidelines for kappa
grading (<0.20 as poor, 0.21–0.40 as fair, 0.41–0.60 as
Fig. 1 Scatter diagram showing linear positive correlation between CDAI and DAS-28 scores (Spearman’s correlation coefficient (rho) = 0.95, p <0.001
Fig. 2 Scatter diagram showing linear positive correlation between SDAI and CDAI (Spearman’s correlation coefficient (rho) = 0.90, p <0.001
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moderate, 0.61–0.80 as good, and 0.81–1.00 as very
good) [11]. Findings with P value less than 0.05 were
considered significant.
Using DAS-28ESR as gold standard, the sensitivity and
specificity of CDAI and SDAI cut offs were determined
to predict levels of disease activity by area under receiver
operator characteristics curves (AUROC).
Results
Of the 103 patients who were included in the study, 90
were females and 13 were males. The mean age of the
patients was 49.7 ± 11.4 years (mean ± SD) and the median
duration of illness was 8 (3–14) years. Demographic pro-
file of patients and the mean values by core set of variables
were shown in (Table 1).
Patients were put under 4 groups of disease activity
based on predefined cut off values of DAS-28, CDAI
and SDAI (Table 2). Most of our patients (›60 %) were
classified under moderate and high disease activity when
DAS-28, CDAI and SDAI criteria were used.
There was an excellent correlation between DAS-28 and
CDAI (r= 0.95, p <0.001) (Fig. 1), CDAI and SDAI (r = 0.90,
p <0.001) (Fig. 2), and DAS-28 and SDAI (r = 0.92,
p <0.001) (Fig. 3).
There was a good inter-rater alignment between the
DAS-28 and CDAI (weighted k = 0.743) and there was a
moderate inter-rater alignment between the DAS-28 and
SDAI (weighted k = 0.60), and between the SDAI and
CDAI (weighted k = 0.589) (Table 3).
A Receiver Operating Characteristic (ROC) curve (Fig. 4)
was constructed to determine the sensitivity and specifi-
city of different values of CDAI and SDAI which would
differentiate between a DAS28 value greater than and less
than 5.1 (high disease activity). The best combination of
sensitivity (97 %) and specificity (85.3 %) was provided
by a CDAI value of 18.5 (with 95 % confidence interval
94.2–98.1). Similarly the highest sensitivity (97.6 %) and
specificity (62.2 %) were given by SDAI value of 24 (with
95 % confidence interval 87.5–94.18) (Table 4).
Discussion
This study is the first Moroccan case study to compare
the performance of both CDAI and SDAI in evaluation
of disease activity in patients with RA.
Our study showed that there was a direct and excel-
lent correlation between DAS-28 and CDAI, and SDAI
and DAS-28. The comparison of the number of patients
under each disease activity category, according to the
disease activity indexes using weighted kappa-statistics,
revealed a good alignment between the CDAI and DAS-
28 but a moderate alignment between the SDAI and
DAS-28. The excellent correlation was only at group
level but not per each single patient. In addition to that,
CDAI had high sensitivity, high specificity and high area
under the curve. These results agreed with other studies
which showed that CDAI is a valid and comparable tool
to DAS28 [12–14]. We found no significant difference in
Fig. 3 Scatter diagram showing linear positive correlation between SDAI and DAS-28 scores (Spearman’s correlation coefficient (rho) = 0.92,
p <0.001
Table 3 Measurement of agreement between DAS28, CDAI and
SDAI in 103 RA patients
Variables Weighted K value P value
CDAI 0.743 <0.001
SDAI 0.60 <0.001
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test performance and AUROC of CDAI and SDAI while
assessing disease activity. This suggests that CDAI is a
valid alternative to SDAI as seen in many studies [3, 15].
We also observed that the cut offs suggested by our
study and other various Western studies vary slightly
and hence the proposed EULAR cut offs can be used
universally to differentiate between different grades of
disease activity with only minor modifications. These re-
sults were also found in Indian population [15].
The management of RA has changed radically over the
last 10 years, with the introduction of new drugs and
treatment strategies and with the emergence of new con-
cepts of disease severity, treatment targets, and means of
evaluating treatment effects [13]. The CDAI is a more
simplified than the DAS28 because it is a simple sum-
mation score requiring nothing more complex than
addition [9]. Furthermore, our study showed that CDAI
performs equally well as SDAI. So we suggest that this
simple clinical tool should be used more often instead of
ordering ESR/CRP at every patient visit and without the
need of any calculating device. Since it can essentially be
evaluated everywhere and at anytime, it may facilitate
decision-making by physicians and helps to avoid lags in
efficient treatment adaptation for RA patients. Such
scores may be easier to understand by the patients and
encourage them to keep track of their “index”. This can
improve patient’s adherence to treatment regimen.
The strength of this study resides in comparing the
performance of both CDAI and SDAI for measuring dis-
ease activity and deriving sensitivity and specificity for
cut offs proposed by various studies, which has not been
done previously in any Moroccan study.
The small number of patients included in our study
may be seen as a limited sample. Therefore, other stud-
ies with a larger patient number would be considered
more interesting.
Conclusion
On the basis of the study results and related statistics, it is
suggested that CDAI and SDAI had good correlation with
DAS-28 for disease activity assessment in Rheumatoid
Table 4 Validity of CDAI and SDAI in comparison to DAS28 in
103 RA patients
Test variable AUC 95 % CI Sensitivity Specificity p value
CDAI 0.962 0.94–0.98 97 % 85.3 % 0.000
SDAI 0.908 0.87–0.94 97.6 % 62.2 % 0.000
Fig. 4 ROC curve illustrating the sensitivity and 1-specificity values for different values of CDAI corresponding to a DAS28>5.1; AUC, area under
the curve; CI, confidence interval
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Arthritis patients. The cut-off values for CDAI and SDAI
used in western literature can be used with minor modifi-
cations in Moroccan scenario. In contrast to DAS28 and
SDAI, CDAI can be obtained at any time and in any
setting without the need of any lab value or any
calculator/computer device. Therefore, CDAI is a very
useful disease activity assessment tool in daily clinical
practice for RA patients.
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